Page last updated: 2024-11-04

ibudilast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ibudilast is a drug that was originally developed to treat asthma, but it has been found to have potential therapeutic benefits in a variety of other conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and spinal cord injury. Ibudilast is a phosphodiesterase inhibitor, which means that it blocks the breakdown of cyclic adenosine monophosphate (cAMP). cAMP is a messenger molecule that plays an important role in many cellular processes, including inflammation, neuroprotection, and memory formation. Ibudilast's ability to inhibit phosphodiesterase activity has been shown to reduce inflammation, protect neurons from damage, and improve cognitive function in animal models of disease. Ibudilast is currently in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. It is also being investigated for the treatment of spinal cord injury, stroke, and traumatic brain injury. Ibudilast is generally well-tolerated, but it can cause some side effects, such as headache, nausea, and dizziness. Ibudilast is a promising drug for the treatment of a variety of conditions, and it is currently being studied in a number of clinical trials. Its mechanism of action, its potential for therapeutic use, and its safety profile are all being investigated in ongoing research.'

Cross-References

ID SourceID
PubMed CID3671
CHEMBL ID19449
CHEBI ID31684
SCHEMBL ID30390
MeSH IDM0115560

Synonyms (126)

Synonym
AC-1044
HMS3268O11
AB00698306-06
BRD-K16444452-001-03-4
ibudilast ,
mn-166
pinatos
av-411
eyevinal
ketas
kc-404
EU-0100599
I0157_SIGMA ,
ibudilast, >=99% (hplc), solid
3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine
ibudilastum [latin]
1-propanone, 2-methyl-1-(2-(1-methylethyl)pyrazolo(1,5-a)pyridin-3-yl)-
ke tas
1-(2-isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone
ibudilast [inn:jan]
pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-
brn 0656579
lopac-i-0157
NCGC00015542-01
tocris-1694
NCGC00025261-01
LOPAC0_000599
smr000326961
MLS000862198
ketas (tn)
ibudilast (jp17/inn)
50847-11-5
D01385
NCGC00025261-03
NCGC00025261-02
av411
av 411
NCGC00015542-03
HMS2089B21
I 0157 ,
1-(2-isopropylh-pyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one
bdbm50240404
(ibudilast)1-(2-isopropyl-pyrazolo[1,5-a]pyridin-3-yl)-2-methyl-propan-1-one
I0740
3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
NCGC00015542-06
CHEMBL19449 ,
DB05266
L003042
ibudilast-d3 (major)
FT-0654591
2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
NCGC00025261-04
HMS3261H20
cas-50847-11-5
tox21_113503
dtxcid2028933
dtxsid7049007 ,
2-methyl-1-(2-propan-2-yl-3-pyrazolo[1,5-a]pyridinyl)-1-propanone
A828320
2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
AVL ,
CCG-204688
HMS2233H08
NCGC00015542-02
NCGC00015542-05
NCGC00015542-04
1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one (ibudilast)
5-24-03-00396 (beilstein handbook reference)
ibudilastum
m0tth61xc5 ,
unii-m0tth61xc5
2-isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine
BCP9000768
ibudilast (jan/inn)
FT-0670255
BCPP000209
LP00599
AKOS015895123
S4837
gtpl7399
HMS3374P02
1-(2-isopropylpyrazolo(1,5-.alpha.)pyridin-3-yl)-2-methyl-1-propanone
ibudilast [mart.]
ibudilast [jan]
ibudilast [inn]
ibudilast [mi]
ibudilast [who-dd]
HY-B0763
1-(2-isopropyl-pyrazolo[1,5-a]pyridin-3-yl)-2-methyl-propan-1-one
1-(2-isopropyl-pyrazolo[1,5-alpha]pyridin-3-yl)-2-methyl-propan-1-one
1-(2-isopropylpyrazolo[1,5-alpha]pyridin-3-yl)-2-methylpropan-1-one
ZJVFLBOZORBYFE-UHFFFAOYSA-N
2-isopropyl-3-isobutyrylpyrazolo[1,5-a]pyridine
1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one
SCHEMBL30390
tox21_113503_1
NCGC00015542-07
H-20256
tox21_500599
NCGC00261284-01
2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone
mfcd00864808
1-propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-
J-512714
sr-01000075927
SR-01000075927-1
CHEBI:31684
SR-01000075927-6
SR-01000075927-3
HMS3715L09
3-isobutyryl-2-isopropyl-pyrazolo(1,5-a)pyridine
SY051343
F20666
HMS3676B20
kc-404;av-411;mn-166
ibudilast,(s)
Q261167
BCP02335
HMS3412B20
SB19092
SDCCGSBI-0050581.P002
HMS3886M03
NCGC00015542-17
EN300-18563279
Z2588063484

Research Excerpts

Overview

Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist. It is effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells.

ExcerptReferenceRelevance
"Ibudilast is a non-selective phosphodiesterase (PDE) inhibitor and glial cell modulator which has shown great promise for the treatment of drug and alcohol use disorders in recent clinical studies. "( Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats.
Friedman, V; Hu, M; Kelly, TJ; Liu, QS; Liu, X; Mu, L; Yu, H; Zhao, L, 2021
)
3.51
"Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist."( Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023
)
2.01
"Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells."( Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model.
Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023
)
1.93
"Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor. "( Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample With Alcohol Use Disorder.
Cummings, JR; Ray, LA; Tomiyama, AJ,
)
1.86
"Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood."( Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018
)
2.64
"Ibudilast (AV-411) is a non-selective inhibitor of cyclic nucleotide phosphodiesterase (PDE). "( Pharmacokinetic profiles of 5 mg/kg ibudilast, a phosphodiesterase inhibitor, orally administered to dogs in fasted and non-fasted states. A preliminary study.
De Vito, V; Giorgi, M; Kowalski, CJ; Lisowski, A; Owen, H; Poapolathep, A; Łebkowska-Wieruszewska, B, 2018
)
2.2
"Ibudilast is a well-tolerated, orally available phosphodiesterase 4 (PDE4) inhibitor used to treat asthma and stroke. "( Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis.
Clanchy, FIL; Williams, RO, 2019
)
3.4
"Ibudilast is an anti-inflammatory glial attenuator and non-selective phosphodiesterase inhibitor currently undergoing clinical evaluations for methamphetamine, opiate, and alcohol abuse disorders."( Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats.
Beardsley, PM; Bowers, MS; Hahn, Y; Knapp, PE; Poland, RS, 2016
)
2.6
"Ibudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP)."( Ibudilast for the treatment of multiple sclerosis.
Goodman, AD; Gyang, T; Smith, AD, 2016
)
2.6
"Ibudilast is an inhibitor of macrophage migration inhibitor factor and phosphodiesterases-4 and -10 and exhibits possible neuroprotective properties."( Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Agius, M; Ashokkumar, A; Bashir, K; Bermel, R; Coffey, CS; Cohen, B; Conwit, R; Coyle, P; Cudkowicz, ME; Delgado, S; Dewitt, D; Ecklund, D; Flores, A; Fox, RJ; Giesser, B; Gleason, T; Goldman, M; Goodman, A; Jubelt, B; Klawiter, EC; Koepp, M; Lava, N; Long, J; Lynch, S; Matsuda, K; McGovern, M; Miravalle, A; Moses, H; Naismith, R; Natarajan, S; Ontaneda, D; Perumal, J; Racke, M; Ramachandran, S; Repovic, P; Riley, C; Severson, C; Shinnar, S; Skaramagas, T; Suski, V; Thornell, B; Weinstock-Gutman, B; Yadav, V; Yankey, J; Zabeti, A, 2016
)
1.37
"Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%."( Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
Bujarski, S; Heinzerling, K; Miotto, K; Ray, LA; Roche, DJ; Shoptaw, S, 2017
)
1.44
"Ibudilast (IBD) is a non‑selective (3, 4, 10, 11) phosphodiesterase (PDE) inhibitor, used mainly as a bronchodilator for the treatment of bronchial asthma. "( Ibudilast: a non‑selective phosphodiesterase inhibitor in brain disorders.
Kurkowska-Jastrzębska, I; Mirowska-Guzel, D; Schwenkgrub, J; Zaremba, M, 2017
)
3.34
"Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. "( Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.
Hutchinson, M; Johnson, K; Rolan, P, 2009
)
3.24
"Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). "( Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof, F; Drulovic, J; Hulst, HE; Landin, R; Matsuda, K; Uitdehaag, BM, 2010
)
3.25
"Ibudilast is a non-selective cyclic AMP phosphodiesterase inhibitor that has recently shown promise as a treatment for neuropathic pain via its ability to attenuate glial cell activation."( Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells.
Kiebala, M; Maggirwar, SB, 2011
)
2.53
"Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation."( Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.
Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007
)
2.5
"Ibudilast is a prostacyclin-mediated vasodilator and antiplatelet agent. "( Efficacy of Ibudilast on lower limb circulation of diabetic patients with minimally impaired baseline flow: a study using color Doppler ultrasonography and laser Doppler flowmetry.
Asakura, Y; Asano, M; Bannai, C; Mizutani, M; Okuda, Y; Sone, H; Yamashita, K, 1995
)
2.11

Effects

Ibudilast (KC-404) has anti-inflammatory activities through its inhibitory effect on the expression of adhesion molecules on eosinophils. It has also been found to have an analgesic action for neuropathic pain at doses 5-10 times higher than those used in asthma therapy.

ExcerptReferenceRelevance
"Ibudilast treatment has restored crucial ASD-related behavioural abnormalities, potentially through neuroprotection. "( Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023
)
2.64
"Ibudilast has also been found to have an analgesic action for neuropathic pain at doses 5-10 times higher than those used in asthma therapy."( Pharmacokinetic profiles of 5 mg/kg ibudilast, a phosphodiesterase inhibitor, orally administered to dogs in fasted and non-fasted states. A preliminary study.
De Vito, V; Giorgi, M; Kowalski, CJ; Lisowski, A; Owen, H; Poapolathep, A; Łebkowska-Wieruszewska, B, 2018
)
1.48
"Ibudilast (KC-404) has anti-inflammatory activities through its inhibitory effect on the expression of adhesion molecules on eosinophils."( Inhibitory effect of ibudilast (KC-404) on the expression of the beta2 integrin family on an eosinophilic cell line (EoL-1).
Chihara, J; Hayashi, N; Honda, K; Kayaba, H; Kurachi, D; Saito, N; Urayama, O; Yamamoto, T, 1998
)
2.06

Actions

Ibudilast is known to produce beneficial effects in several neurological disorders including neuropathic pain, multiple sclerosis, etc. Ibudilst did not inhibit 12-deoxyphorbol 13-isobutyrate (DPB)-induced contraction in the presence of verapamil.

ExcerptReferenceRelevance
"Ibudilast is known to produce beneficial effects in several neurological disorders including neuropathic pain, multiple sclerosis, etc."( Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023
)
1.92
"Ibudilast did not inhibit 12-deoxyphorbol 13-isobutyrate (DPB)-induced contraction in the presence of verapamil."( Ibudilast-induced decreases in cytosolic Ca(2+) level and contraction in rat aorta.
Kaneda, T; Konno, Y; Nakajyo, S; Shimizu, K; Urakawa, N, 2007
)
2.5
"Ibudilast tended to inhibit ADP- or epinephrine-induced platelet aggregation in the presence of HUVECs, but the effects were not statistically significant."( Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells.
Ozaki, Y; Qi, R; Rile, G; Satoh, K; Yatomi, Y, 2001
)
1.38

Treatment

Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments. Treatment significantly attenuated prenatal VPA exposure associated social interaction and spatial learning/memory deficits, anxiety, hyperactivity, and increased nociceptive threshold.

ExcerptReferenceRelevance
"Ibudilast pretreatments enhanced GABAergic inhibition and did not further change cocaine-induced potentiation of excitation, leading to normalization of the E/I ratio."( Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats.
Friedman, V; Hu, M; Kelly, TJ; Liu, QS; Liu, X; Mu, L; Yu, H; Zhao, L, 2021
)
2.79
"Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex."( Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022
)
1.83
"Ibudilast treatment has restored crucial ASD-related behavioural abnormalities, potentially through neuroprotection. "( Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023
)
2.64
"Ibudilast's treatment effect was observed compared to placebo for thalamic MTR ("( Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Cohen, JA; Fox, RJ; Mahajan, KR; Nakamura, K; Ontaneda, D; Zheng, Y, 2023
)
2.76
"Ibudilast pretreatment attenuated HSR-induced TLR4 protein expression, reduced myocardial MDA and TNF-α levels, and protected against cardiac dysfunction."( Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor α.
Wang, JJ; Wu, NC,
)
2.3
"Ibudilast pretreatment reduced myocardial TLR4 expression, decreased MDA and TNF-α levels, and protected against HSR-induced decrease in LV contractility, prolonged LV relaxation time, and increased diastolic stiffness."( Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor α.
Wang, JJ; Wu, NC,
)
3.02
"Ibudilast treatment was associated with a reduction in gray matter atrophy. "( Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Bermel, RA; Coffey, CS; Fedler, J; Fox, RJ; Goebel, C; Goodman, AD; Kearney, M; Klawiter, EC; Klingner, E; Naismith, RT; Nakamura, K; Narayanan, S; Yankey, J, 2021
)
2.45
"Ibudilast treatment was not associated with a change in either serum or CSF NfL."( Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Barro, C; Bermel, RA; Chase, M; Coffey, CS; Fox, RJ; Goodman, AD; Karafa, M; Klawiter, EC; Konig, V; Kuhle, J; Naismith, RT; Raska, P, 2021
)
2.31
"Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments."( Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats.
Cao, J; Fardell, JE; Forrest, DRL; Hutchinson, MR; Johnston, IN; Matsos, A; Si, E; Tan, M, 2017
)
2.62
"Ibudilast treatment had similar rates of adverse events compared with placebo, and there was no significant augmentation of cardiovascular effects of methamphetamine. "( Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
Andrenyak, DM; DeYoung, DZ; Furst, BA; Heinzerling, KG; Moody, DE; Shoptaw, SJ; Swanson, AN; Tsuang, J; Wu, YN; Yi, Y, 2016
)
2.12
"Ibudilast treatment did not significantly alter this increase."( The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain.
Broadhead, A; Hama, AT; Lorrain, DS; Sagen, J, 2012
)
1.36
"Treatment with ibudilast significantly attenuated prenatal VPA exposure associated social interaction and spatial learning/memory deficits, anxiety, hyperactivity, and increased nociceptive threshold, and it decreased oxidative stress markers, pro-inflammatory markers (IL-1β, TNF-α, IL-6), and % area of GFAP-positive cells and restored neuronal damage."( Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023
)
1.55
"Treatment with ibudilast allowed for deeper extinction of active lever pressing. "( Ibudilast reverses the decrease in the synaptic signaling protein phosphatidylethanolamine-binding protein 1 (PEBP1) produced by chronic methamphetamine intake in rats.
Bastola, DR; Bevins, RA; Charntikov, S; Pendyala, G; Pittenger, ST; Thapa, I, 2015
)
2.21
"Treatment with ibudilast down-regulated these molecules, suppressed macrophage migration into the aneurysm wall, and inhibited PDE-4 activation and the elevation of cyclic adenosine monophosphate in endothelial cells."( Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats.
Kitazato, KT; Nagahiro, S; Satomi, J; Tada, Y; Tamura, T; Yagi, K, 2010
)
2.14
"Treatment with ibudilast was generally safe and well tolerated."( Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof, F; Drulovic, J; Hulst, HE; Landin, R; Matsuda, K; Uitdehaag, BM, 2010
)
2.14

Toxicity

Methamphetamine administration during ibudilast treatment was well tolerated without additive cardiovascular effects or serious adverse events. The most common adverse event was mild, transient nausea.

ExcerptReferenceRelevance
" No serious adverse events occurred."( Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.
Chang, E; Davidson, JB; Gibbons, JA; Gross, MI; He, L; Johnson, KW; Jones, D; Rolan, P; Sanftner, LM, 2008
)
1.79
" Ibudilast was generally well-tolerated with mild, transient nausea reported as the most common adverse event (66."( Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
Hutchinson, MR; Johnson, JL; Johnson, K; Kwok, YH; Rolan, PE; Sumracki, NM; Swift, JE; Tuke, J; Williams, DB, 2015
)
1.64
" We monitored cardiovascular effects, methamphetamine pharmacokinetics, and reported adverse events."( Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
Andrenyak, DM; DeYoung, DZ; Furst, BA; Heinzerling, KG; Moody, DE; Shoptaw, SJ; Swanson, AN; Tsuang, J; Wu, YN; Yi, Y, 2016
)
0.68
"Ibudilast treatment had similar rates of adverse events compared with placebo, and there was no significant augmentation of cardiovascular effects of methamphetamine."( Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
Andrenyak, DM; DeYoung, DZ; Furst, BA; Heinzerling, KG; Moody, DE; Shoptaw, SJ; Swanson, AN; Tsuang, J; Wu, YN; Yi, Y, 2016
)
2.12
"Methamphetamine administration during ibudilast treatment was well tolerated without additive cardiovascular effects or serious adverse events, providing initial safety data to pursue ibudilast's effectiveness for the treatment of methamphetamine dependence."( Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
Andrenyak, DM; DeYoung, DZ; Furst, BA; Heinzerling, KG; Moody, DE; Shoptaw, SJ; Swanson, AN; Tsuang, J; Wu, YN; Yi, Y, 2016
)
0.95
" In conclusion, these results suggest that tacrolimus translocation into the brain and neuronal damage in the cerebral cortex and CA1 are the underlying mechanisms of tacrolimus-induced neurotoxicity and that ibudilast could be a protective agent against this adverse event."( Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity.
Egashira, N; Fu, R; Hirota, T; Ieiri, I; Matsukane, R; Tsuchiya, Y; Yamamoto, S; Zhang, W, 2022
)
1.21

Pharmacokinetics

The mean half-life for ibudilast was 19 h and median T(max) was 4-6 h. The study found no significant effect on oxaliplatin pharmacokinetics, and is unlikely to influence 5-fluorouracil.

ExcerptReferenceRelevance
"After being processed by 3P87 pharmacokinetics program, the experiment data showed that the pharmacokinetic parameters of the tablets and the capsules were AUC0-->infinity: 740."( [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
Cheng, Q; Jia, Y; Li, T; Pang, Y; Sun, J; Wang, Z, 2003
)
0.32
" The lower limit of quantitation in human serum was 1 ng/mL, which is sensitive enough for pharmacokinetic studies."( Determination of ibudilast in human serum by high-performance liquid chromatography for pharmacokinetic study.
Cho, HY; Lee, YB; Yoon, H, 2010
)
0.7
" The wide degree of variation observed in area under the curve (AUC) suggests that the investigation of population pharmacokinetic modelling is warranted."( Pharmacokinetic profiles of 5 mg/kg ibudilast, a phosphodiesterase inhibitor, orally administered to dogs in fasted and non-fasted states. A preliminary study.
De Vito, V; Giorgi, M; Kowalski, CJ; Lisowski, A; Owen, H; Poapolathep, A; Łebkowska-Wieruszewska, B, 2018
)
0.76
" A population pharmacokinetic approach was used to determine oxaliplatin and 5-fluorouracil pharmacokinetics with and without ibudilast."( Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
Blinman, PL; Dhillon, HM; Galettis, P; McLachlan, AJ; Proschogo, N; Reuter, SE; Teng, C; Vardy, JL, 2020
)
2.21
" Pharmacokinetic analysis indicates ibudilast has no significant effect on oxaliplatin pharmacokinetics, and is unlikely to influence pharmacokinetics of 5-fluorouracil."( Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer.
Blinman, PL; Dhillon, HM; Galettis, P; McLachlan, AJ; Proschogo, N; Reuter, SE; Teng, C; Vardy, JL, 2020
)
2.28

Compound-Compound Interactions

ExcerptReferenceRelevance
" The in vivo antithrombotic property of ibudilast (CAS 50847-11-5), a phosphodiesterase 4 (PDE4) inhibitor, was evaluated in a photochemically-induced guinea pig carotid artery thrombosis model in combination with low-dose ASA."( Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury.
Hoshina, K; Manita, S; Matsuzawa, S; Miyata, Y; Ooie, T; Sasahara, T; Sueyoshi, S; Yasue, T, 2012
)
2.09

Bioavailability

ExcerptReferenceRelevance
"To study the pharmacokinetics and relative bioavailability of KC-404 sustained release tablets and capsules in healthy volunteers."( [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
Cheng, Q; Jia, Y; Li, T; Pang, Y; Sun, J; Wang, Z, 2003
)
0.32
" The relative bioavailability of KC-404 sustained release tablets was 102."( [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
Cheng, Q; Jia, Y; Li, T; Pang, Y; Sun, J; Wang, Z, 2003
)
0.32
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Non-treatment-seeking participants with current alcohol use disorder were randomized to receive twice-daily dosing with ibudilast (50 mg) or placebo. Using the current dosing regimen, ibudirast does not improve headache or reduce opioid use in patients with MOH without mandated opioid withdrawal.

ExcerptRelevanceReference
" In the second experiment, using the same dosing regimen, sampling continued 3 h after morphine or saline in AV411- or vehicle-treated rats."( The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.
Bland, ST; Hutchinson, MR; Johnson, KW; Maier, SF; Watkins, LR, 2009
)
0.35
" The variability among species cannot be explained by intrinsic clearance, which in intravenous dosing experiments shows only moderate interspecies variation (13-41 l h(-1) m(-2))."( Cross-species comparisons of the pharmacokinetics of ibudilast.
Gaeta, FC; Gibbons, JA; Gross, MI; Johnson, KW; Sanftner, LM; Suzuki, BM, 2009
)
0.6
" The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens."( Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014
)
0.66
"Using the current dosing regimen, ibudilast does not improve headache or reduce opioid use in patients with MOH without mandated opioid withdrawal."( Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
Hutchinson, MR; Johnson, JL; Johnson, K; Kwok, YH; Rolan, PE; Sumracki, NM; Swift, JE; Tuke, J; Williams, DB, 2015
)
1.01
"Adult, non-treatment seeking, MA-dependent volunteers (N=11) received oral placebo, moderate ibudilast (40 mg), and high-dose ibudilast (100mg) via twice-daily dosing for 7 days each in an inpatient setting."( Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study.
Heinzerling, KG; Roche, DJ; Shoptaw, S; Swanson, A-N; Worley, MJ, 2016
)
2.1
" Dogs in group 1 (n=3) were fasted for at least 10 hours overnight before the beginning of the experiment and 4 h following dosing while dogs in group 2 (n=3) received food ad libitum."( Pharmacokinetic profiles of 5 mg/kg ibudilast, a phosphodiesterase inhibitor, orally administered to dogs in fasted and non-fasted states. A preliminary study.
De Vito, V; Giorgi, M; Kowalski, CJ; Lisowski, A; Owen, H; Poapolathep, A; Łebkowska-Wieruszewska, B, 2018
)
0.76
"Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25)."( Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.
Burnette, EM; Grodin, EN; Irwin, MR; Ray, LA, 2021
)
2.27
" Here we show that systemic administration of ibudilast dose-dependently reduced cocaine self-administration under fixed- and progressive-ratio reinforcement schedules in rats and shifted cocaine dose-response curves downward."( Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats.
Friedman, V; Hu, M; Kelly, TJ; Liu, QS; Liu, X; Mu, L; Yu, H; Zhao, L, 2021
)
2.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrazolopyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (49)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.61530.003245.467312,589.2998AID2517
glp-1 receptor, partialHomo sapiens (human)Potency9.45600.01846.806014.1254AID624172; AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.63530.100020.879379.4328AID588453; AID588456
TDP1 proteinHomo sapiens (human)Potency20.59100.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.40700.000714.592883.7951AID1259369; AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency14.96400.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.03100.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency26.60320.005428.02631,258.9301AID1346982
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency7.49720.001024.504861.6448AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00070.023723.228263.5986AID743222
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.02510.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.03980.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.16230.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.63100.00636.904339.8107AID883
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.44670.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.44670.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.44670.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.78280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.73880.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.63100.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency1.00001.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)103.00000.00001.18439.6140AID598349
Macrophage migration inhibitory factorHomo sapiens (human)Ki30.90000.03802.22565.5500AID1677643
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)0.46930.00001.068010.0000AID1720008; AID363371; AID695680
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)1.71000.00001.104010.0000AID1720009; AID363372; AID598348
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)IC50 (µMol)0.23900.00001.465110.0000AID1720036; AID363373
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.16600.00001.146310.0000AID1720037; AID363151
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)299.00000.00031.990110.0000AID598347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Macrophage migration inhibitory factorHomo sapiens (human)Kd1.40000.06862.69549.0400AID1677644
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)EC50 (µMol)0.90000.01701.21593.4000AID695683
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (104)

Processvia Protein(s)Taxonomy
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
extracellular spacecAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
ciliumcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID363375Inhibition of fMLP-induced LTB4 biosynthesis in human whole blood2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID598349Inhibition of human PDE5A catalytic domain using cAMP/cGMP substrate2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
AID598347Inhibition of human PDE3A catalytic domain using cAMP/cGMP substrate2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
AID80621Inhibitory activity of the Compound was tested against U-46619 induced contraction of guinea pig trachea at 3*10e-8 M concentration.1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Analogues of natural phloroglucinols as antagonists against both thromboxane A2 and leukotriene D4.
AID363151Inhibition of human PDE4D2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID695683Induction of SQSTM1-dependent intracellular redistribution of GFP-tagged PDE4A4 assessed as maximal accretion of enzyme into foci2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID695687Induction of SQSTM1-dependent intracellular redistribution of GFP-tagged PDE4A4 assessed as maximal accretion of enzyme into foci relative to rolipram2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID1677643Non-competitive inhibition of recombinant human MIF assessed as inhibition constant using varying levels of p-hydroxyphenylpyruvate as substrate by Lineweaver-Burk plot analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Inhibition of Macrophage Migration Inhibitory Factor by a Chimera of Two Allosteric Binders.
AID1677644Binding affinity to recombinant biotinylated human MIF expressed in Escherichia coli BL21 DE3 by surface plasmon resonance assay2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Inhibition of Macrophage Migration Inhibitory Factor by a Chimera of Two Allosteric Binders.
AID363374Inhibition of LPS-induced TNFalpha release in human whole blood2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1720008Inhibition of human PDE4A expressed in insect sf9 cells using [3H]-cAMP as substrate2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID1720009Inhibition of human PDE4B expressed in insect sf9 cells using [3H]-cAMP as substrate2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID363373Inhibition of human PDE4C2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID695680Inhibition of full-length PDE4A4 using cAMP as substrate by two-step radiochemical assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID363371Inhibition of human PDE4A2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID598348Inhibition of human PDE4B catalytic domain using cAMP/cGMP substrate2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
AID1720036Inhibition of human PDE4C expressed in insect sf9 cells using [3H]-cAMP as substrate2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID363372Inhibition of human PDE4B2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1720037Inhibition of human PDE4D expressed in insect sf9 cells using [3H]-cAMP as substrate2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Advances in the Development of Phosphodiesterase-4 Inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1345264Human phosphodiesterase 5A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
AID1345234Human phosphodiesterase 4B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1345251Human phosphodiesterase 4A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1345205Human phosphodiesterase 3A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
AID1345281Human phosphodiesterase 4C (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (196)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (9.18)18.7374
1990's32 (16.33)18.2507
2000's38 (19.39)29.6817
2010's69 (35.20)24.3611
2020's39 (19.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.78 (24.57)
Research Supply Index5.45 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index81.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (15.50%)5.53%
Reviews12 (6.00%)6.00%
Case Studies5 (2.50%)4.05%
Observational0 (0.00%)0.25%
Other152 (76.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Relative Bioavailability Study of an Extended Release (ER) Tablet Formulation of MN-166 (Ibudilast) Compared to an Intermediate Release (IR) Capsule Formulation in Healthy Volunteers [NCT04054206]Phase 112 participants (Actual)Interventional2019-06-24Completed
Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy [NCT04631471]Phase 3400 participants (Anticipated)Interventional2021-12-22Recruiting
Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study [NCT01317992]Phase 1/Phase 240 participants (Anticipated)Interventional2011-04-30Recruiting
Bioequivalence Study of Two MN-166 (Ibudilast) 50 mg Extended Release Tablet Formulations Compared With MN-166 (Ibudilast) 10mg Capsules in Healthy Volunteers [NCT03533387]Phase 128 participants (Actual)Interventional2018-04-11Completed
A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) [NCT02714036]Phase 1/Phase 235 participants (Actual)Interventional2016-05-06Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome [NCT04429555]Phase 240 participants (Anticipated)Interventional2021-01-11Active, not recruiting
REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM) [NCT05513560]Phase 2/Phase 31,000 participants (Anticipated)Interventional2023-05-31Recruiting
Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST [NCT01389193]Phase 133 participants (Actual)Interventional2013-06-30Completed
Development of Ibudilast as a Novel Treatment for Alcohol Dependence [NCT02025998]Phase 124 participants (Actual)Interventional2013-12-31Completed
Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast [NCT03341078]Phase 2120 participants (Anticipated)Interventional2019-05-01Recruiting
Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers [NCT01740414]Phase 228 participants (Actual)Interventional2012-11-30Completed
Phase I Safety Interaction Trial of Ibudilast With Methamphetamine [NCT01217970]Phase 111 participants (Actual)Interventional2011-01-31Completed
A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS) [NCT02238626]Phase 270 participants (Actual)Interventional2014-09-30Completed
Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder [NCT03489850]Phase 252 participants (Actual)Interventional2018-07-16Completed
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder [NCT03594435]Phase 2102 participants (Actual)Interventional2018-10-01Completed
Randomized Trial of Ibudilast for Methamphetamine Dependence [NCT01860807]Phase 2125 participants (Actual)Interventional2013-07-31Completed
A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder [NCT05414240]Phase 250 participants (Anticipated)Interventional2023-01-14Recruiting
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma [NCT03782415]Phase 1/Phase 250 participants (Anticipated)Interventional2018-12-29Active, not recruiting
The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal [NCT00723177]Phase 230 participants (Actual)Interventional2008-10-31Completed
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis [NCT01982942]Phase 2255 participants (Actual)Interventional2013-11-30Completed
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis [NCT04057898]Phase 2/Phase 3230 participants (Anticipated)Interventional2020-05-28Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00723177 (2) [back to overview]Subjective Opioid Withdrawal Scale Score (SOWS)
NCT00723177 (2) [back to overview]The Effects of AV411 on the Analgesic Effects of Oxycodone.
NCT01740414 (3) [back to overview]Drug Self-administration Breakpoint
NCT01740414 (3) [back to overview]Pain Intensity
NCT01740414 (3) [back to overview]Positive Subjective Effects to Oxycodone
NCT01860807 (1) [back to overview]Methamphetamine Use
NCT01982942 (6) [back to overview]Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).
NCT01982942 (6) [back to overview]Magnetization Transfer Ratio (MTR) Imaging in Normal-appearing Brain Tissue
NCT01982942 (6) [back to overview]New T1 Lesions Since Baseline
NCT01982942 (6) [back to overview]Percentage of Participants With Adverse Events.
NCT01982942 (6) [back to overview]Retinal Nerve Fiber Layer as Measured by Optical Coherence Tomography (OCT).
NCT01982942 (6) [back to overview]Diffusion Tensor Imaging (DTI) in Descending Pyramidal White Matter Tracts
NCT02238626 (7) [back to overview]Clinical Global Impression of Change (CGIC)
NCT02238626 (7) [back to overview]Mean Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Total Score From Baseline to Month 6
NCT02238626 (7) [back to overview]Muscle Strength
NCT02238626 (7) [back to overview]Respiratory Function
NCT02238626 (7) [back to overview]Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALS
NCT02238626 (7) [back to overview]The Mean Change in Baseline to Month 6 in Quality of Life as Measured by the Amyotrophic Lateral Sclerosis Assessment Questionnaire - 5
NCT02238626 (7) [back to overview]Use of Non-invasive Ventilation
NCT03489850 (4) [back to overview]Any Drinking
NCT03489850 (4) [back to overview]Heavy Drinking
NCT03489850 (4) [back to overview]Negative Affect
NCT03489850 (4) [back to overview]Ventral Striatum Activation

Subjective Opioid Withdrawal Scale Score (SOWS)

Measures severity of opioid withdrawal in opioid dependent populations (0-64). Larger values indicate more severe withdrawal. (NCT00723177)
Timeframe: Measured at the end of each two-week maintenance period (i.e., Placebo, Low AV411, High AV411).

Interventionunits on a scale (Mean)
Placebo16
Low-dose AV4114
High-dose AV41124

[back to top]

The Effects of AV411 on the Analgesic Effects of Oxycodone.

The McGill Pain Questionnaire (Melzack, 1987) was used to assess pain experience immediately following the immersion of the hand in 4 degree Celsius water. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60. Larger scores indicate greater pain levels. (NCT00723177)
Timeframe: Measured at the end of each AV411 of the three two-week maintenance periods

Interventionunits on a scale (Mean)
Placebo40
Low-dose AV41142
High-dose AV41138

[back to top]

Drug Self-administration Breakpoint

Participants are allowed to perform an operant task (click on a mouse) in order to receive a dose drug under investigation (oxycodone dose 0 mg, 15 mg, or 30 mg). The drug breakpoint is the maximum number of responses (mouse clicks) the participant was willing to make to receive the drug. Within the context of abuse liability studies, larger breakpoints represent greater abuse potential of a drug. (NCT01740414)
Timeframe: 42 days

InterventionClicks on a computer mouse (Mean)
MN-166 + Oxy 0 mg347
MN-166 + Oxy 15 mg363
MN-166 + Oxy 30 mg1472
Placebo + Oxy 0 mg43
Placebo + Oxy 15 mg1650
Placebo + Oxy 30 mg2459

[back to top]

Pain Intensity

"15-item shortened form of the McGill Pain Questionnaire (Melzack, 1987) that is used to assess the sensory and affective dimensions of the pain experienced Participants describe their experience of pain by choosing among a series of possible answers (None [score=1], Mild [score=2], Moderate [score=3], or Severe [score=4]). They were asked to describe the pain as Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-Burning, Aching, Heavy, Tender, Splitting, Tired-Exhausting, Sickening, Fearful, and Punishing-Cruel. Scores were added across all 15 items to generate a sum score, which ranged between 15 and 60." (NCT01740414)
Timeframe: 42 days

Interventionunits on a scale (Mean)
MN-166 + Oxy 0 mg30
MN-166 + Oxy 15 mg25
MN-166 + Oxy 30 mg26
Placebo Oxy 0 mg31
Placebo + Oxy 15 mg29
Placebo + Oxy 30 mg27

[back to top]

Positive Subjective Effects to Oxycodone

"Participants are shown a 100-mm line and asked to indicate on that line the extent to which they agree with the descriptor of the drug effect such as Liking/Liked the Drug. On this visual analog scale participants were instructed that the Left/ 0 mm point on the line represents not at all, while the right/100 mm point represents Extremely." (NCT01740414)
Timeframe: 42 days

Interventionunits on a scale (Mean)
MN-166 + Oxy 0 mg.8
MN-166 + Oxy 15 mg10.9
MN-166 + Oxy 30 mg24.2
Placebo + Oxy 0 mg.9
Placebo + Oxy 15 mg15.5
Placebo + Oxy 30 mg22.7

[back to top]

Methamphetamine Use

End of treatment methamphetamine abstinence (NCT01860807)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Ibudilast9
Placebo10

[back to top]

Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).

To evaluate the activity of ibudilast (100 mg/day) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), calculated as the ratio of brain parenchymal tissue volume to the total volume contained within the brain surface contour. (NCT01982942)
Timeframe: 96 weeks

Interventionratio (Mean)
Ibudilast-0.00168
Placebo Oral Capsule-0.00392

[back to top]

Magnetization Transfer Ratio (MTR) Imaging in Normal-appearing Brain Tissue

A magnetization transfer MRI as a marker of brain myelin content including the cerebral cortex could be useful. MT imaging provides access to the restricted protons, which are located in biologically interesting tissue regions.Cortical and normal appearing grey matter MTR correlates strongly with measures of disability such as the multiple sclerosis functional composite score and can show treatment effects. (NCT01982942)
Timeframe: 96 weeks

Interventionratio (Least Squares Mean)
Ibudilast0.325
Placebo Oral Capsule0.247

[back to top]

New T1 Lesions Since Baseline

New T1 lesions since baseline as measured by least square mean (90% confidence interval). (NCT01982942)
Timeframe: 96 weeks

Interventionlesions (Least Squares Mean)
Ibudilast0.355
Placebo Oral Capsule0.317

[back to top]

Percentage of Participants With Adverse Events.

Safety Measures: percentage of participants who experienced treatment-emergent adverse events, clinically significant abnormal laboratory and electrocardiogram results. (NCT01982942)
Timeframe: 96 weeks

Interventionpercentage receiving study medication (Number)
Ibudilast92.2
Placebo Oral Capsule88.1

[back to top]

Retinal Nerve Fiber Layer as Measured by Optical Coherence Tomography (OCT).

Mean retinal nerve fiber layer thickness from baseline measured by Optical coherence tomography (OCT), a non-invasive imaging technique used to obtain high-resolution cross-sectional images of the retina. Increase in thickness is considered improvement. (NCT01982942)
Timeframe: 96 weeks

Interventionmicrometers (Least Squares Mean)
Ibudilast83.0
Placebo Oral Capsule79.5

[back to top]

Diffusion Tensor Imaging (DTI) in Descending Pyramidal White Matter Tracts

Diffusion tensor imaging estimates the three-dimensional diffusion of water in brain tissue and has been explored as an outcome in MS. (NCT01982942)
Timeframe: 48 weeks

,
Intervention10^3/mm^2/s (Least Squares Mean)
Left axial diffusivity meanLeft radial diffusivity meanRight axial diffusivity meanRight radial diffusivity mean
Ibudilast0.0001-0.00770.0014-0.0029
Placebo Oral Capsule-0.00060.0027-0.00170.0046

[back to top]

Clinical Global Impression of Change (CGIC)

A scale used to provide a global rating of illness severity, improvement, and response to treatment. It is a 3-item observer rating scale and uses a 7-point rating scale. The scale was rated relative to the previous standard of care visit prior to randomization for entry, i.e., -3 much much much worse, -2 much much worse, - 1 much worse, 0 no change, +1 much better, +2 much much better, +3 much, much, much better. Ratings were provided by the Investigator. The greater the mean decrease from baseline to Month 6, the group was considered worse off. For example, -2 is worse than -1. The greater the mean increase from baseline to Month 6, the group was considered improved. For example, 2 is better than 1. (NCT02238626)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Placebo (for MN-166) (Early ALS Cohort)-1.0
MN-166 (Early ALS Cohort)-1.4
Placebo (for MN-166) (Advanced ALS Cohort)-1.3
MN-166 (Advanced ALS Cohort)-1.6

[back to top]

Mean Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Total Score From Baseline to Month 6

Functional activity as assessed by the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised from baseline visit to Month 6. The best possible score is 48; the worst possible score is 0. Typically, ALS scores decline. In this outcome, the change in score will be a negative value, e.g., -4, -8, etc. The higher negative value indicates greater decline in functional activity (change in score -8 is worse than change in score -4). (NCT02238626)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Placebo (for MN-166) (Early ALS Cohort)-3.8
MN-166 (Early ALS Cohort)-4.5
Placebo (for MN-166) (Advanced ALS Cohort)-2.2
MN-166 (Advanced ALS Cohort)-4.8

[back to top]

Muscle Strength

Muscle strength measured by manual muscle testing (MMT) and instrumented hand-held dynamometry. Maximum muscle strength is assessed by measuring the best of 2 handgrips represented as kilograms (kg). The greater the change from baseline to month 6, the worse off the subject is. For example, a change of -0.50 is worse than -0.40. (NCT02238626)
Timeframe: 6 months

Interventionweight (kg) (Mean)
Placebo (for MN-166) (Early ALS Cohort)-3.9
MN-166 (Early ALS Cohort)-4.9
Placebo (for MN-166) (Advanced ALS Cohort)-1.3
MN-166 (Advanced ALS Cohort)-4.4

[back to top]

Respiratory Function

Change in respiratory function (breathing capacity) from baseline to Month 6, as measured by slow vital capacity, in which the patient breathes into a spirometer slowly until the lungs are cleared of air. SVC is measured in liters (L). The greater the mean change from baseline to 6 months, the worse the outcome. For example, -10 is worse than -6. (NCT02238626)
Timeframe: 6 months

InterventionLiters (Mean)
Placebo (for MN-166) Early ALS Cohort-6.1
MN-166 (Early ALS Cohort)-10.1
Placebo (for MN-166) (Advanced ALS Cohort)-12.2
MN-166 (Advanced ALS Cohort)-11.1

[back to top]

Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALS

Safety will be assessed by monitoring and recording all treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs) and discontinuations due to TEAEs and Additional assessments will include regular monitoring of hematology, blood chemistry, and urine values, regular measurement of vital signs, ECGs, medical history, physical and neurological examinations. (NCT02238626)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Placebo (for MN-166) (Early ALS Cohort)17
MN-16634
Placebo (for MN-166) (Advanced ALS Cohort)8
MN-166 (Advanced ALS Cohort)11

[back to top]

The Mean Change in Baseline to Month 6 in Quality of Life as Measured by the Amyotrophic Lateral Sclerosis Assessment Questionnaire - 5

A patient self-reported questionnaire specifically designed to measure 5 areas of health: physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional functioning. The ALSAQ-5 is brief and easy to complete questionnaire and has undergone rigorous testing for validity, reliability, and sensitivity to change and has been shown to be a robust tool for assessing ALS. The lowest possible score is 0 and the highest possible score is 20. The greater the mean decrease from baseline to Month 6, the group was considered worse off. For example, -2 is worse than -1. The greater the mean increase from baseline to Month 6, the group was considered improved. For example, 2 is better than 1. (NCT02238626)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Placebo (for MN-166)2.1
MN-1661.6
Placebo (for MN-166) (Advanced ALS Cohort)-0.70
MN-166 (Advanced ALS Cohort)4.8

[back to top]

Use of Non-invasive Ventilation

Non-invasive ventilation (NIV) utilization measured by clinically indicated prescription for NIV intervention and time to clinically indicated prescription for NIV intervention in each group (for early ALS subjects only). This is intended to count the number of subjects who had to go on non-invasive ventilation, as prescribed by the Principal Investigator, during study participation. (NCT02238626)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Placebo (for MN-166) (Early ALS Cohort)6
MN-166 (Early ALS Cohort)10

[back to top]

Any Drinking

Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Interventionpredicted probability in percent (Number)
Ibudilast59.25
Placebo63.63

[back to top]

Heavy Drinking

Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group. (NCT03489850)
Timeframe: 14 days

Interventionpredicted probability in percent (Number)
Ibudilast24.16
Placebo36.80

[back to top]

Negative Affect

"Negative affect as measured by self-reported ratings of Downhearted, Discouraged, Uneasy, and Anxious. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood." (NCT03489850)
Timeframe: Assessed through daily prompts throughout the 2-week study period.

Interventionunits (Least Squares Mean)
Ibudilast2.91
Placebo2.47

[back to top]

Ventral Striatum Activation

Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space. (NCT03489850)
Timeframe: Day 8

Interventionpercent signal change (Mean)
Ibudilast-0.08
Placebo0.14

[back to top]